Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.000773%
Abdominal pain07.01.05.0020.001660%
Abdominal pain lower07.01.05.010--Not Available
Abdominal tenderness07.01.05.0040.000143%Not Available
Acute respiratory distress syndrome22.01.03.001; 24.03.02.034; 10.02.01.0670.000143%
Agitation19.06.02.001; 17.02.05.012--
Agitation neonatal18.04.04.002; 17.02.05.0280.000143%Not Available
Agranulocytosis01.02.03.0010.000429%Not Available
Alanine aminotransferase increased13.03.04.005--
Alcohol intolerance14.02.01.0010.000358%
Altered state of consciousness19.07.01.003; 17.02.04.0010.000215%Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.0060.006653%
Anaphylactic shock24.06.02.004; 10.01.07.0020.004221%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000501%Not Available
Angioedema22.04.02.008; 10.01.05.009; 23.04.01.0010.002504%Not Available
Anosmia17.04.04.001; 22.04.03.0060.000143%
Aplastic anaemia01.03.03.002--Not Available
Arteriosclerosis coronary artery02.02.01.011; 24.04.04.0120.000215%Not Available
Arteriospasm coronary12.02.01.031; 24.04.04.005; 02.02.02.0050.000429%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asphyxia22.02.02.001; 12.01.08.0110.000143%Not Available
Auditory disorder04.02.03.0020.000143%Not Available
Back pain15.03.04.0050.001574%
Blindness17.17.01.003; 06.02.10.0030.000715%Not Available
Blister12.01.06.002; 23.03.01.0010.000916%Not Available
Blood bilirubin increased13.03.04.018--
Blood creatinine decreased13.13.01.003--Not Available
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene